ABSTRACT
INTRODUCTION
Atherosclerosis is a chronic inflammatory process and the major pathology responsible for cardiovascular disease, which is now the leading cause of global mortality (1) . This pathology results from the accumulation of lipids, immune cells and extracellular matrix within arterial walls, causing flow limitation (2) . Atherosclerotic lesions progress and may rupture and thrombose, occluding the vessel and leading to myocardial infarcts or strokes. Macrophages are immune cells involved in most key pathways for the development of atherosclerosis including uptake of oxidized LDL, cholesterol efflux, foam cell and fatty streak formation, local proliferation, apoptosis, programmed removal of dead cells or efferocytosis, necrotic core formation and contribution to plaque stability (2) .
Liver X receptors (LXRs) are ligand activated transcription factors that play vital roles in cholesterol homeostasis (3) and inflammation (4) . LXRs are expressed as two isotypes; LXRα and LXRβ, which display 78% sequence homology, yet vary in their tissue expression and regulation (5) . Both LXRs are endogenously activated by oxidized metabolites of cholesterol (6) and intermediates of the cholesterol biosynthesis pathway(7), as well as by various synthetic ligands (8) .
Pharmacological activation of these receptors has been demonstrated to modulate a range of lipid and inflammatory disorders (9) . With regards to atherosclerosis, activating LXRs attenuates atherosclerosis progression(3) via promotion of cholesterol efflux through lipid-laden macrophages present in the atherosclerotic lesions, inhibition of vascular inflammation (4) and possibly by affecting other aspects of lipid metabolism (10) . Additionally, ligand-activated LXR promotes CCR7-dependent plaque regression (11) . Functional studies in macrophages further indicate that LXRα is required for a robust anti-atherosclerotic response to LXR ligands and LXRα plays a selective role in limiting atherosclerosis in response to hyperlipidemia (12) .
LXRα transcriptional activity can be modulated by several posttranslational modifications (5) including phosphorylation at serine (S) 198 in the human sequence, corresponding to S196 in the mouse orthologue. We have demonstrated that modulation of LXRα phosphorylation significantly modifies its target gene repertoire in macrophage cell lines overexpressing the receptor, thereby altering pathways known to be relevant to the development of atherosclerosis (13, 14) . Interestingly, we previously showed phosphorylated S196-LXRα is present in progressive atherosclerotic lesions (14) suggesting LXRα phosphorylation at this residue could be important for the development of atherosclerotic plaques. However, the specific contribution of myeloid LXRα phosphorylation to atherosclerosis development remains unknown. 4 To investigate this, we have generated a mouse model specifically expressing a Ser-to-Ala phosphorylation mutant of LXRα in myeloid cells (M-S196A) in the LDLR-deficient (Ldlr-KO) atherosclerotic background (M-S196A Ldlr-KO ). Disrupting LXRα phosphorylation in myeloid cells including macrophages promotes plaque burden, yet modulates plaque phenotype to acquire distinctive characteristics such as smaller necrotic cores and thinner fibrous caps encapsulating the lesions. These phenotypic changes are consistent with a reprogrammed macrophage transcriptome. Notably, cell cycle progression and proliferation pathways are markedly induced in M-S196A Ldlr-KO macrophages, specifically the expression of the FoxM1 transcription factor and several of its targets. This is associated with increased lesion-resident cell proliferation in the LXRα phospho-mutant mice. In addition, changes in the expression of various phagocytic molecules result in enhanced macrophage efferocytosis thus explaining the reduced necrotic cores present in M-S196A mice. Interestingly, most of the phosphorylation sensitive genes identified are not subject to LXR ligand regulation and we show that global transcriptional changes in response to impaired LXRα phosphorylation under dietary perturbation are markedly distinct from those revealed by ligand activation. Overall, these findings demonstrate LXRα phosphorylation at S196 determines atherosclerotic plaque progression by promoting changes in local cell proliferation, efferocytosis and necrotic core formation.
RESULTS

Impaired myeloid LXRα phosphorylation promotes atherosclerosis
To investigate the impact of macrophage LXRα phosphorylation on the development of atherosclerosis we generated a new mouse model expressing a serine to alanine mutation at residue 196 in LXRα in myeloid cells (M-S196A) on a pro-atherosclerotic (LDLR-deficient or Ldlr-KO) background (M-S196A Ldlr-KO ) (Fig. S1A ). Effective expression of Cre-driven targeting construct introducing S196A knock-in in the sense strand was demonstrated in M-S196A Ldlr-KO compared to WT Ldrl-KO control littermates (Fig. S1B ). Mice were fed a fat-rich Western diet (WD) to accelerate plaque progression. M-S196A Ldlr-KO mice developed normally and no change in body weight before, during or after Western diet (WD) feeding was observed ( Fig. S1C-E ). There were no detectable changes in basal metabolic characteristics including total cholesterol, HDL or LDL/VLDL levels and amount of triglycerides, free fatty acids and insulin in the plasma of M-S196A Ldlr-KO compared to WT Ldlr-KO ( Fig. S2A-G) . Interestingly, M-S196A Ldlr-KO mice showed a significant increase in atherosclerosis plaque burden in their aortas as measured by en face oil red O staining (Fig. 1A) and aortic root plaque coverage (Fig. 1B) . This was however, not associated with changes in the levels of CD68+ positive cells in the lesions (Fig. 1C ).
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Changes in LXRα phosphorylation at Ser196 reprogram global macrophage gene expression in the context of diet-induced atherosclerosis
To explore in more detail the pathways underlying the changes observed in atherosclerosis development we investigated the transcriptomic profiles of macrophages differentiated from the bone marrows of mice exposed to the WD. RNA-seq analysis revealed significant genome wide changes in transcript levels ( Fig. 2A, B) . LXRα-S196A significantly induced (460) or reduced (210) gene expression. Hallmark pathway analysis identified G2M checkpoint and E2F targets to be markedly enriched indicating cell cycle and cell proliferation pathways are induced in the mutantexpressing macrophages (Fig 2C and Fig. S3A,B) . This was further confirmed by Reactome pathway analysis (Table S1 ). Several genes involved in these processes were regulated over 2-fold including cell proliferation marker Mik67 or Ki67 (4.58-fold, p=3.46E-43) (Fig 2D) . Concomitant to these changes in cell proliferation genes, there was a substantial reduction in the expression of genes associated with the immune response ( Fig 2C,E, Fig. S3C and Table S2 ). We observed opposing changes in the expression of chemokine receptors involved in monocyte trafficking to atherosclerotic lesions and some of the chemokines they bind to (15) expression was diminished in LXRα-S196A macrophages compared to WT macrophages. Such differential expression of chemokine receptors and their ligands may explain the lack of change in the overall number of CD68+ cells retained in the plaques of M-S196A Ldlr-KO mice.
M-S196A induces expression of FoxM1 and lesion-resident cell proliferation
Examination of the RNA-seq datasets revealed LXRα-S196A cells expressed almost 3-fold (p=7.76E-14) more proto-oncogene FoxM1 compared to macrophages expressing wild type LXRα (Fig. 3A,B) . This was also the case for several FoxM1 target genes (16) (Fig. 3A,B) . While LXRα activation was previously shown to inhibit cell proliferation via inhibition of FoxM1 in hepatic carcinoma cells (17) , its regulation in macrophages has never been documented. LXRs modulate gene transcription by heterodimerising with the Retinoid X Receptor (RXR) and binding to specific DNA sequences termed LXR response elements (LXREs) in the transcriptional regulatory regions of their target genes (18) . Notably, specific LXRα occupancy was observed at the FoxM1 gene in macrophages further indicating that FoxM1 is an LXRα target in these cells (Fig. S4A) . The enhanced levels of several pro-mitotic genes suggested cell proliferation could be altered in M-S196A Ldlr-KO macrophages. Indeed macrophages expressing the LXRα-S196A mutant showed about 20% increase in proliferation in culture measured as Ki67 levels (Fig. S4B ). Recent studies have highlighted the important role local macrophage proliferation plays in lesion development (19) .
Consistent with a significant increase in the regulation of FoxM1 and other genes involved in cell 6 cycle pathways, increased proliferation of lesion-resident cells as measured by Ki67 staining was observed in the atherosclerotic plaques of M-S196A Ldlr-KO mice (Fig. 3C,D ) which was associated with increased nuclei content (Fig. S5A ) compared to WT Ldlr-KO . This strongly suggests that enhanced local proliferation in the plaques could contribute to increased plaque size exhibited by M-S196A Ldlr-KO mice as has been postulated (20) (21) (22) .
M-196A
Ldlr-KO mice display phenotypic changes in their necrotic cores and fibrous caps
The observed changes in gene expression suggest a complex interaction of pathways involved in the progression of atherosclerosis. Unexpectedly, despite their larger size, size-matched atherosclerotic lesions in M-S196A Ldlr-KO mice display smaller necrotic cores (Fig. 4A ).
Programmed cell removal or efferocytosis has been shown to strongly impact the formation of necrotic cores in advanced plaques (23) . In agreement with this, macrophage engulfment of apoptotic cells was significantly increased ( 
Col5a1 (0.6-fold, P=3.4x10 -03 ), and Col6a1 (0.5-fold, P=4.2x10 -05 ) and increased levels of matrix degrading molecules such as Mmp8 (1.57-fold, P=6.1x10 -10 ) and Mmp12 (1.48-fold, P=8.8x10 -6 ).
Overall, this data highlights the complex phenotypic changes present in atherosclerotic lesions resulting from changes in LXRα phosphorylation.
Disrupted LXRα phosphorylation at Ser196 alters ligand responses in macrophages.
Our findings indicate that in the context of an atherogenic diet, changes in LXRα phosphorylation modulate the macrophage transcriptome and promote atherosclerotic plaque burden. To further understand the magnitude of the transcriptional changes imposed by the LXRα phosphorylation mutant, we next examined whether WT and S196A expressing macrophages respond differently to an LXR ligand and explored the differences in global transcript changes between ligand activation and reduced LXRα phosphorylation. RNA-seq analysis was performed on bone marrow-7 derived macrophages from M-196A Ldlr-KO mice exposed to WD for 12 weeks and cultured in the presence of vehicle or LXR ligand GW3965. GW ligand activation promoted changes in macrophage gene expression that were different in cells expressing the S196A mutant compared to WT macrophages ( Fig. S6A-C ). GSEA analysis revealed the pathways subject to changes in LXRα phosphorylation in the presence of the LXR ligand are similar to those seen in the absence of GW (Fig. S6D ). For instance, genes involved in nuclear division and cell cycle remained strongly induced by LXRα-S196A, further emphasizing the importance of LXRα phosphorylation in the modulation of these pathways. Remarkably, it became apparent that while a small subset of genes were differentially regulated by the mutant only in the context of the ligand (94 induced and 50 reduced compared to WT cells), most differences in gene expression were observed in the absence of ligand (Fig. 6A,B) . Additionally, our datasets also showed that ligand responses were similar in both WT and mutant expressing macrophages (Fig. 6C,D) . However, the identity of the genes regulated was distinct, with only 47 genes (about half of the total number) being regulated by both WT and S196A forms of LXRα (Fig. 6C ). Further analysis revealed that both the magnitude of the response and the identity of the genes were strikingly different between the response to the ligand (regulation by GW in either WT or S196A cells) and to phosphorylation (modulation by LXRα-S196A compared to WT) ( Fig. 6E,F ). This highlights the significance of phosphorylation in rewiring the LXR-modulated transcriptome.
Finally, we investigated whether this dichotomy between ligand and phosphorylation-induced responses was apparent in the regulation of the phosphorylation-sensitive gene FoxM1 and some of its target genes. FoxM1 was not significantly affected by exposure to the LXR ligand in WT LdlrKO cells (Fig. 5G) . By contrast, GW3965 activation markedly reduced FoxM1 mRNA levels in M-S196A Ldlr-KO macrophages (Fig. 5G ). This regulatory pattern was recapitulated by most FoxM1 targets examined ( Fig. 5G and Fig. S6E ). In addition, established transcriptional regulators of FoxM1 were strongly (Top2a, Rad51, Check2) or moderately (Melk,) induced in M-S196A
Ldlr-KO cells in unstimulated conditions compared to WT LdlrKO cells (Fig. 5H) . Consistent with the known anti-proliferative effects of LXR ligands, the expression of these genes was strongly attenuated by GW3965, particularly in the mutant cells. Other phosphorylation-sensitive genes implicated in cell cycle progression mimic this mode of regulation (Fig S6F) .
Overall, our findings suggest that LXRα phosphorylation at Ser196 is a powerful means of regulating LXRα transcriptional activity that has important consequences for macrophage biology and for the progression of a metabolic, inflammatory and proliferative disease such as atherosclerosis.
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DISCUSSION
The macrophage regulatory nodes that determine how the atherosclerotic lesion progresses in response to dietary challenges are not fully understood. Liver X receptors have key roles in the regulation of macrophage lipid homeostasis and inflammation and as such they strongly modulate the progression of metabolic diseases such as atherosclerosis (3) . The importance of these receptors in disease development has been mainly gleaned from studies evaluating the consequences of its pharmacological or genetic manipulation. However, it remained unknown whether alternative modulation of the activity of these receptors, for instance, by altering post-translational modifications of the receptor, could shape the pro-atherogenic responses of fatrich diets thus altering disease development. We previously showed LXRα is phosphorylated in cholesterol-loaded macrophages and in progressive atherosclerotic plaques (13) . We have now explored the impact of LXRα phosphorylation on atherosclerosis development by expressing an
LXRα Ser-to-Ala mutant, previously shown to disrupt LXRα phosphorylation (13) , specifically in myeloid cells on the LDLR null background (M-LXRαS196A Ldlr-KO ).
LXRαS196A expression in cells of the myeloid lineage, including macrophages, increases atherosclerotic plaque burden (Fig. 1 ). This is consistent with an enhanced number of proliferating lesion-resident cells ( We now demonstrate that chronic disruption of LXRα phosphorylation in macrophages enhances
FoxM1 expression and several of its associated regulators and targets driving cell cycle progression(16) (Fig. 3A,B) . This is associated with increased lesional cell proliferation (Fig. 3C,D) and cell content (Fig. S5A) , consistent with larger atherosclerotic lesions. Amongst FoxM1 regulators, Bub1b (or BubR1, increased 1.9 fold, P=1.26x10 -6 in the LXRα-S196A-expressing macrophages) and has been shown to alter atherosclerosis, as impaired expression of BubR1 results in decreased macrophage proliferation and attenuated atherogenesis (47) . Furthermore, LXRα-S196A macrophages show decreased mRNA expression of the FoxM1 inhibitor SASH1 (46) (0.8-fold, P=1.33x10 -4 ), which was implicated in the development of atherosclerosis in people that smoke through its monocytic up-regulation. Overall, our findings further highlight the importance of this set of molecules in atherosclerosis progression.
Importantly, we show evidence that reduced LXRα phosphorylation during atherosclerosis development reprograms the macrophage transcriptome (Fig. 2) . Global gene expression analysis (Fig. 5E,F) thus highlighting the importance of this post-translational modification in modulating the activity of LXRα in the context of a metabolic and inflammatory
disease. An example for this is the regulation of FoxM1 expression and its regulated pathways, which are induced in LXRα-S196A-expressing cells (Fig. 3A) . Previous reports have linked LXRα activation with FoxM1 repression in hepatic carcinoma cells (17) . We observed that FoxM1 inhibition by GW3965 is recapitulated in macrophages from mice exposed to a high fat diet that are developing atherosclerotic plaques (Fig. 5G) . However, this is preferentially observed in the LXRα phosphorylation mutant-expressing cells. In fact, most FoxM1 targets and modulators as well as other factors involved in the G2/M cell cycle transition mirror this pattern of regulation ( Beyond changes in cell proliferation, the enhanced plaque burden in M-LXRαS196A
Ldlr-KO mice is likely the result of the complex modulation of additional pathways relevant for atherosclerosis development. LXRα promotes the expression of factors important for macrophage efferocytotic capacity such as the MerTK receptor for apoptotic cells(52) which can influence the formation of the necrotic core and plaque stability (53) . Despite the overall increase in atherosclerosis, we found that size-matched advanced plaques from M-S196A Ldlr-KO mice exhibited significantly reduced necrotic cores (Fig. 4A ) consistent with the increased capacity of M-S196A Ldlr-KO macrophages to engulf apoptotic cells (Fig. 4B& S5A) . Transcriptomic profiling revealed that in addition to the reduced expression of Mertk and its ligand Gas6, several genes known to promote phagocytosis were significantly upregulated in M-S196A Ldlr-KO cells, including the pro-phagocytotic receptors Ccr2(54), Gpr132(55), Itgb3(56) and the bridging molecule 11 Mfge8(57) (Fig. 4C) . This differential expression could explain the increased phagocytic ability of the LXRα phospho-mutant expressing macrophages (Fig. 4B ).
In summary, we have shown that disrupting LXRα phosphorylation in cells of the myeloid lineage, affects the development of atherosclerosis that could be explained through altered cell proliferation and efferocytosis. We also show that chronically modulating LXRα phosphorylation reprograms gene regulation in macrophages under basal conditions and significantly affects their response to ligand stimulation. These findings add to our fundamental knowledge of how LXRα activity can be regulated and introduce novel functional consequences of its modification by phosphorylation which should be heeded to manipulate these receptors for the design of novel cardiovascular therapies.
MATERIALS AND METHODS
Mice.
The S196A floxed (S196A fl/fl ) mouse line was generated by Ozgene Pty Ltd (Bentley WA, Australia). The genomic sequence for the murine LXRα (Nr1h3) The germline mice were crossed to a FLP Recombinase mouse line (58) 
Genotyping
Mice were genotyped by PCR analysis of ear biopsies using Jumpstart Taq DNA Polymerase (Sigma Aldrich) and the following primers: For S198A knock-in, primers R2 and WT identify the 
Diet induced atherosclerosis. Eight-week old WT
Ldlr-KO and M-S196A Ldlr-KO male mice were fed ad libitum a Western diet (WD) (20% Fat, 0.15% Cholesterol; #5342 AIN-7A, Test Diet Limited, UK) for 12 weeks. Mice were fasted overnight prior to sacrifice.
Metabolic tests
Blood was sampled from saphenous vein as previously described (59) . Glucose concentrations were determined in whole blood by a portable meter (Roche Diagnostics, 2 Burgess Hill, UK).
Plasma insulin concentrations were determined by enzyme-linked immunoassay (#EZRMI-13K, Merck Millipore). Plasma total cholesterol and triglyceride levels (Wako Diagnostics), as well as NEFAs (Abcam), were determined by colorimetric enzymatic assay kits as per the manufacturer's recommendations.
Atherosclerosis quantification.
En face analysis of aorta. Mice were perfusion-fixed with phosphate-buffered paraformaldehyde (4% [wt/vol.], pH 7.2) under terminal anaesthesia. The entire aortic tree was dissected free of fat and other tissue. Aortae were stained with oil red O and mounted onto glass slides before imaging (Leica, DFC310FX) under a dissection microscope (Leica, MZ10F). Lesion area of whole aorta was analysed using Image J.
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Aortic sinus. Hearts were formalin-fixed, paraffin-embedded and 5 µm aortic sinus sections were stained with stained with hematoxylin and eosin (H&E). Stained sections were scanned with NanoZoomer Digital slide scanner (Hamamatsu). Percentage atherosclerotic lesion were determined using Image J by averaging 3 sections from each mouse with 30-50 µm intervals between sections(59).
Macrophage content.
Immunohistochemistry staining was performed at the UCL IQPath Laboratory using the Ventana Discovery XT instrument, using the Ventana DAB Map detection Kit (760-124). For pre-treatment Ventana Protease 1 (equivalent to pronase, 760-2018) was used. CD68 primary antibody (AbD Serotec #MCA1957), followed by Rabbit anti Mouse (#E0354 Dako). Stained sections were scanned with NanoZoomer Digital slide scanner (Hamamatsu). Macrophage content was quantified in the plaque using Image J.
Plaque complexity. Percent necrotic core was measured in H&E stained aortic roots as acellular area (60) using Image J.
Cell culture
Bone marrow derived macrophage culture. Bone Marrow-derived Macrophages (BMDM) were prepared as in (61) Jurkat culture. Jurkat cells were cultured in RPMI supplemented with 10% FBS, and passaged every two days to maintain a cell concentration not exceeding 1x10 6 cells/mL.
Efferocytosis.
Jurkat cells or BMDM were labeled for 1 hr with calcein AM and apoptosis was induced by UV irradiation. Apoptotic cells were added to monolayers of BMDM at a ratio of 1:1. After 30 min of coculture, non-ingested apoptotic cells were removed, and slides fixed in 1% PFA. Images were captured (microscope: Zeiss Axio Vert.A1, camera: Zeiss Axiocam 503 mono) and ingested apoptotic cells quantified as in (62) RNA extraction and quantification.
Total RNA from was extracted with TRIzol Reagent (Invitrogen). Sample concentration and purity was determined using a NanoDrop™ 1000 Spectrophotometer and cDNA was synthesized using the qScript cDNA Synthesis Kit (Quanta). Specific genes were amplified and quantified by quantitative Real Time-PCR, using the PerfeCTa SYBR Green FastMix (Quanta) on an MX3000p system (Agilent). Primer sequences are available upon request The relative amount of mRNAs was calculated using the comparative Ct method and normalized to the expression of cyclophylin (63) .
Protein isolation and immunoblotting
Total cellular protein lysates (30µg) were loaded onto a 10% SDS-PAGE gel, electrophoresed and transferred onto a PVDF membrane. The membrane was probed with anti-FoxM1 (G-5: sc-376471, Santa Cruz), anti-Akt and anti-phosphorylated Akt (#8200S, Cell Signaling) and anti-Hsp90 (sc-7947, Santa Cruz) overnight in 2.5% BSA, TBS, followed by incubation with anti-rabbit (PO448, Dako) or anti-mouse (NA931VS, GE Healthcare) horseradish-peroxidase-tagged antibodies.
Chemiluminescence (ECL 2 Western Blotting Substrate, Pierce) was used to visualise proteins.
RNA sequencing and analysis
Total RNA was extracted using TRIzol reagent (Life technologies) and cDNA libraries were prepared using reagents and protocols supplied with the Stranded mRNA-Seq Kit (Kapa Biosystems). Briefly, poly-A tailed RNA was purified using paramagnetic oligo-dT beads from 200 nanograms of total RNA, with a RNA Integrity Number above 7.5 as determined by the Agilent Bioanalyzer (Agilent). The purified RNA was chemically fragmented and cDNA was synthesised using random primers (Kapa Biosystems). Adapter-ligated DNA library was amplified with 12
cycles of PCR and library fragment was estimated using the Agilent TapeStation 2200.Library concentration was determined using the Qubit DNA HS assay (Life Technologies). Libraries were 15 sequenced on an Illumina NextSeq 500, NCS v2. 
ChIP-sequencing
Immortalized bone marrow derived-macrophages (iBMDM) from LXRαβ -/-mice have been described (67) . N-terminus 3xFLAG-tagged LXRα or LXRβwere ectopically expressed in LXR-null iBMDM using a pBabe-puro retroviral expression system as described (68) . A control LXRαβ M.G. and I.P.T designed experiments, analysed and interpreted data and wrote the manuscript.
I.P.T. conceived the study, secured funding and supervised all aspects of the work. 
